DK0929574T3 - Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer - Google Patents

Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer

Info

Publication number
DK0929574T3
DK0929574T3 DK97940663T DK97940663T DK0929574T3 DK 0929574 T3 DK0929574 T3 DK 0929574T3 DK 97940663 T DK97940663 T DK 97940663T DK 97940663 T DK97940663 T DK 97940663T DK 0929574 T3 DK0929574 T3 DK 0929574T3
Authority
DK
Denmark
Prior art keywords
beta
peptide
amyloid peptide
compounds
amino
Prior art date
Application number
DK97940663T
Other languages
English (en)
Inventor
Mark A Findeis
Malcolm L Gefter
Gary Musso
Ethan R Signer
Susan Molineaux
Joseph Chin
Jung-Ja Lee
Michael Kelley
Christopher C Arico-Muendel
James Wakefield
Sonja Komar-Panicucci
Kathryn Phillips
Neil J Hayward
Original Assignee
Praecis Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/703,675 external-priority patent/US6303567B1/en
Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc
Application granted granted Critical
Publication of DK0929574T3 publication Critical patent/DK0929574T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK97940663T 1996-08-27 1997-08-27 Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer DK0929574T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/703,675 US6303567B1 (en) 1995-03-14 1996-08-27 Modulators of β-amyloid peptide aggregation comprising D-amino acids
US89734297A 1997-07-21 1997-07-21
PCT/US1997/015166 WO1998008868A1 (en) 1996-08-27 1997-08-27 MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS

Publications (1)

Publication Number Publication Date
DK0929574T3 true DK0929574T3 (da) 2005-10-31

Family

ID=27107183

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97940663T DK0929574T3 (da) 1996-08-27 1997-08-27 Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer

Country Status (11)

Country Link
EP (2) EP1586584A1 (da)
JP (1) JP2001500852A (da)
AT (1) ATE298765T1 (da)
AU (1) AU741199B2 (da)
CA (1) CA2262453A1 (da)
DE (1) DE69733655T2 (da)
DK (1) DK0929574T3 (da)
ES (1) ES2245003T3 (da)
HK (1) HK1021741A1 (da)
PT (1) PT929574E (da)
WO (1) WO1998008868A1 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
EP1015013A4 (en) * 1997-01-10 2002-07-24 Massachusetts Inst Technology TREATMENT OF NEUROTOXICITY IN ALZHEIMER'S DISEASE BY BETA-AMYLOID PEPTIDES
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU781292B2 (en) 1999-03-04 2005-05-12 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1870419A3 (en) * 1999-03-04 2008-01-02 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
CN1437442A (zh) * 1999-11-05 2003-08-20 阿克松尼克斯公司 适于体内应用治疗与折叠成淀粉样蛋白、淀粉样蛋白样沉积物的异常蛋白或其富含β－折叠的致病性前体有关的疾病的肽类似物和模拟物
AU784312B2 (en) * 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001058470A2 (en) * 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
WO2002035987A2 (en) 2000-11-03 2002-05-10 Massachusetts Institute Of Technology METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US7067550B2 (en) 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
CN101979093B (zh) * 2001-01-17 2013-04-24 罗伯特·H·齐默尔 含有肽原料药和其它不易吸收的活性成分的组合物及其应用
WO2003055521A1 (fr) * 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Remedes contre les troubles cognitifs legers
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US20050148650A1 (en) 2002-03-01 2005-07-07 Shigenori Ohkawa Antidepressant
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en) 2002-04-30 2005-01-25 Pharmacia & Upjohn Company Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1638517A4 (en) * 2003-06-30 2010-01-06 Univ Tel Aviv Future Tech Dev PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF THESE DISEASES
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
EP2089419A2 (en) * 2006-10-27 2009-08-19 Zapaloid Limited Inhibition of beta-amyloid aggregation
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
RU2500685C2 (ru) 2006-11-10 2013-12-10 Кара Терапеутикс, Инк Синтетические пептидные амиды
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011009394A (es) 2009-03-10 2011-10-11 Takeda Pharmaceutical Derivados de benzofurano.
MX2013003749A (es) 2010-10-07 2013-05-09 Takeda Pharmaceutical Derivados de 1,4-oxazepano.
EP2640737B1 (en) 2010-11-15 2018-08-29 Ramot at Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
ME03372B (me) 2011-10-07 2020-01-20 Takeda Pharmaceuticals Co Jedinjenja 1-arilkarbonil-4-oksipiperidina korisna za tretman neurodegenerativnih bolesti
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
UA115156C2 (uk) 2012-12-11 2017-09-25 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014163162A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
EP3152198B1 (en) 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
EP3594203B1 (en) 2017-03-08 2021-08-04 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112020000823A2 (pt) 2017-08-03 2020-07-21 Takeda Pharmaceutical Company Limited composto, medicamento, métodos para ativar um receptor de orexina tipo 2 e para profilaxia ou tratamento de narcolepsia, e, uso de um composto ou sal.
WO2019189945A1 (en) 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US20210269420A1 (en) 2018-06-29 2021-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
MA54823A (fr) 2019-01-24 2022-04-27 Takeda Pharmaceuticals Co Composé hétérocyclique et son utilisation
TW202110824A (zh) 2019-05-24 2021-03-16 美商賽吉醫療公司 化合物、組合物及使用方法
EP4028004A1 (en) 2019-09-13 2022-07-20 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
WO2021048821A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2023550654A (ja) 2020-11-25 2023-12-04 セージ セラピューティクス， インコーポレイテッド 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物
WO2022190060A1 (en) 2021-03-12 2022-09-15 Takeda Pharmaceutical Company Limited An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
CA3215906A1 (en) 2021-04-02 2022-10-06 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for post operation recovery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
US6319498B1 (en) * 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
AU1072897A (en) * 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta

Also Published As

Publication number Publication date
CA2262453A1 (en) 1998-03-05
EP0929574A1 (en) 1999-07-21
AU741199B2 (en) 2001-11-22
JP2001500852A (ja) 2001-01-23
DE69733655D1 (de) 2005-08-04
PT929574E (pt) 2005-11-30
WO1998008868A1 (en) 1998-03-05
ES2245003T3 (es) 2005-12-16
EP0929574B1 (en) 2005-06-29
ATE298765T1 (de) 2005-07-15
DE69733655T2 (de) 2006-04-27
HK1021741A1 (en) 2000-06-30
AU4238797A (en) 1998-03-19
EP1586584A1 (en) 2005-10-19

Similar Documents

Publication Publication Date Title
DK0929574T3 (da) Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
CY1106899T1 (el) Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
DE60041119D1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE69635493D1 (de) Verfahren zur herstellung von l-aminosäuren
BR0209434A (pt) Peptìdeos antimicrobianos e composições
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
DK0506748T3 (da) Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
WO2005060683A3 (en) Small peptides for the treatment of alzheimer’s disease and other beta-amyloid protein fibrillogenesis disorders
ATE167232T1 (de) Protein mit knochenbildungs-eigenschaften und verfahren zu seiner herstellung
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
ES2196088T3 (es) Analogos del factor de crecimiento de los queratinocitos.
DE69227979T2 (de) Modifizierte VIP-Derivate und sie enthaltende pharmazeutische Zusammensetzungen
DE69315730T2 (de) Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
DE69706757T2 (de) Verfahren zur Herstellung von 3-Amino substituierten Crotonaten
EP1870419A3 (en) Modulators of beta-amyloid peptide aggregation comprising d-amino acids
AU1464488A (en) Human rhinovirus peptides
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
DE59915086D1 (de) Rekombinante l-n-carbamoylase aus arthrobacter aurescens, verfahren zur herstellung von l-aminosäuren mittels dieser
DE59810880D1 (de) Verfahren zur Isolierung von 1-[N2-((S-Ethoxycarbonyl)-3-phenylpropyl)-N6-trifluoracetyl]-L-lysyl-L-prolin (Lisinopril(Tfa)ethylester, LPE)
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
DE59707484D1 (de) Verfahren zur Herstellung von 1.4 Bis(aminomethyl) cyclohexan